Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Akin

Showing results (91-100 of 203) with videos related to

Pageof 21
Sort By:
Hematology/Oncology Clinics of North America|October 17, 2003
Mast cell proliferative disorders: current view on variants recognized by the World Health OrganizationPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Autonomic Neuroscience : Basic & Clinical|November 20, 2025
Autonomic function testing and symptom severity in patients with suspected mast cell activation disordersAmro M Stino, Jodi Nelson, Olivia Gutgsell, et al.
The Journal of Allergy and Clinical Immunology|June 9, 2005
Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signatureCan N Kocabas, Akif S Yavuz, Peter E Lipsky, et al.
International Archives of Allergy and Immunology|February 2, 2006
Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosisNataliya M Kushnir-Sukhov, Erica Brittain, James C Reynolds, et al.
Expert Opinion on Biological Therapy|October 16, 2020
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurinJason Gotlib, Hanneke C Kluin-Nelemans, Cem Akin, et al.
The Journal of Allergy and Clinical Immunology|May 31, 2011
Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestationsMatthew J Hamilton, Jason L Hornick, Cem Akin, et al.
Blood|January 26, 2006
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosisNeil P Shah, Francis Y Lee, Roger Luo, et al.
The Journal of Allergy and Clinical Immunology|January 19, 2002
Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptaseKnut Brockow, Cem Akin, Mary Huber, et al.
The Journal of Allergy and Clinical Immunology|July 3, 2014
High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patientTheoharis C Theoharides, Anastasia I Petra, Julia M Stewart, et al.
Blood|April 9, 2004
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibCem Akin, Gerard Fumo, Akif S Yavuz, et al.
Pageof 21

Showing results (91-100 of 203) with videos related to

Sort By:
Pageof 21
Hematology/Oncology Clinics of North America|October 17, 2003
Mast cell proliferative disorders: current view on variants recognized by the World Health OrganizationPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Autonomic Neuroscience : Basic & Clinical|November 20, 2025
Autonomic function testing and symptom severity in patients with suspected mast cell activation disordersAmro M Stino, Jodi Nelson, Olivia Gutgsell, et al.
The Journal of Allergy and Clinical Immunology|June 9, 2005
Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signatureCan N Kocabas, Akif S Yavuz, Peter E Lipsky, et al.
International Archives of Allergy and Immunology|February 2, 2006
Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosisNataliya M Kushnir-Sukhov, Erica Brittain, James C Reynolds, et al.
Expert Opinion on Biological Therapy|October 16, 2020
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurinJason Gotlib, Hanneke C Kluin-Nelemans, Cem Akin, et al.
The Journal of Allergy and Clinical Immunology|May 31, 2011
Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestationsMatthew J Hamilton, Jason L Hornick, Cem Akin, et al.
Blood|January 26, 2006
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosisNeil P Shah, Francis Y Lee, Roger Luo, et al.
The Journal of Allergy and Clinical Immunology|January 19, 2002
Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptaseKnut Brockow, Cem Akin, Mary Huber, et al.
The Journal of Allergy and Clinical Immunology|July 3, 2014
High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patientTheoharis C Theoharides, Anastasia I Petra, Julia M Stewart, et al.
Blood|April 9, 2004
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibCem Akin, Gerard Fumo, Akif S Yavuz, et al.
Pageof 21